Literature DB >> 16932934

EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues.

T Vander Borght1, S Asenbaum, P Bartenstein, C Halldin, O Kapucu, K Van Laere, A Varrone, K Tatsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16932934     DOI： 10.1007/s00259-006-0206-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  19 in total

1.  O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.

Authors:  Dirk Pauleit; Frank Floeth; Kurt Hamacher; Markus J Riemenschneider; Guido Reifenberger; Hans-Wilhelm Müller; Karl Zilles; Heinz H Coenen; Karl-Josef Langen
Journal:  Brain       Date:  2005-02-02       Impact factor: 13.501

2.  Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT.

Authors:  Burkhard Riemann; Karsten Papke; Norbert Hoess; Torsten Kuwert; Matthias Weckesser; Peter Matheja; Hansdetlef Wassmann; Walter Heindel; Otmar Schober
Journal:  Radiology       Date:  2002-11       Impact factor: 11.105

3.  Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas.

Authors:  W A Weber; S Dick; G Reidl; B Dzewas; R Busch; H J Feldmann; M Molls; C B Lumenta; M Schwaiger; A L Grosu
Journal:  J Nucl Med       Date:  2001-08       Impact factor: 10.057

4.  Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine.

Authors:  Dirk Pauleit; Frank Floeth; Hans Herzog; Kurt Hamacher; Lutz Tellmann; Hans-W Müller; Heinz H Coenen; Karl-J Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-15       Impact factor: 9.236

5.  Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology.

Authors:  Lutz W Kracht; Hrvoje Miletic; Susanne Busch; Andreas H Jacobs; Jurgen Voges; Moritz Hoevels; Johannes C Klein; Karl Herholz; Wolf-D Heiss
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

Review 6.  Radiolabeled amino acids: basic aspects and clinical applications in oncology.

Authors:  P L Jager; W Vaalburg; J Pruim; E G de Vries; K J Langen; D A Piers
Journal:  J Nucl Med       Date:  2001-03       Impact factor: 10.057

Review 7.  Fluorinated amino acids for tumour imaging with positron emission tomography.

Authors:  Peter Laverman; Otto C Boerman; Frans H M Corstens; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-01-11       Impact factor: 9.236

8.  Estimation of internal absorbed dose of L-[methyl-11C]methionine using whole-body positron emission tomography.

Authors:  H M Deloar; T Fujiwara; T Nakamura; M Itoh; D Imai; M Miyake; S Watanuki
Journal:  Eur J Nucl Med       Date:  1998-06

9.  Increased tumor uptake of 3-(123)I-Iodo-L-alpha-methyltyrosine after preloading with amino acids: an in vivo animal imaging study.

Authors:  Tony Lahoutte; Vicky Caveliers; Philippe R Franken; Axel Bossuyt; John Mertens; Hendrik Everaert
Journal:  J Nucl Med       Date:  2002-09       Impact factor: 10.057

10.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.

Authors:  Benoit Pirotte; Serge Goldman; Nicolas Massager; Philippe David; David Wikler; Arlette Vandesteene; Isabelle Salmon; Jacques Brotchi; Marc Levivier
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057
View more
  36 in total

1.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Authors:  Cécile Colavolpe; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Béquet-Boucard; Dominique Figarella-Branger; Olivier Mundler; Olivier Chinot; Eric Guedj
Journal:  J Neurooncol       Date:  2011-12-15       Impact factor: 4.130

2.  Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.

Authors:  Nathalie L Albert; Isabel Winkelmann; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Erik Mille; Andrei Todica; Matthias Brendel; Jörg-Christian Tonn; Peter Bartenstein; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-15       Impact factor: 9.236

3.  Reply to "[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.

Authors:  Karl-Josef Langen; Norbert Galldiks
Journal:  Neuro Oncol       Date:  2013-06-07       Impact factor: 12.300

4.  Response to "reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.

Authors:  Markus Hutterer; Martha Nowosielski; Daniel Putzer; Christian la Fougère; Irene J Virgolini; Andreas H Jacobs; Günther Stockhammer
Journal:  Neuro Oncol       Date:  2013-06-19       Impact factor: 12.300

5.  Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas?

Authors:  A Verger; D Taieb; E Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-27       Impact factor: 9.236

6.  Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Andrea Schaefer; Georgios Farmakis; Aleksandar Grgic; Jean R Moringlane; Wolf-Ingo Steudel; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-30       Impact factor: 9.236

7.  Approaches for the optimization of MR protocols in clinical hybrid PET/MRI studies.

Authors:  Maria-Isabel Vargas; Minerva Becker; Valentina Garibotto; Susanne Heinzer; Pierre Loubeyre; Joanna Gariani; Karl Lovblad; Jean-Paul Vallée; Osman Ratib
Journal:  MAGMA       Date:  2012-09-25       Impact factor: 2.310

8.  FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

Authors:  Cécile Colavolpe; Olivier Chinot; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Bequet-Boucard; Emeline Tabouret; Olivier Mundler; Dominique Figarella-Branger; Eric Guedj
Journal:  Neuro Oncol       Date:  2012-02-29       Impact factor: 12.300

9.  Response to: Performance of 18F-FET-PET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: inherent bias in meta-analysis not revealed by quality metrics.

Authors:  Vincent Dunet; John O Prior
Journal:  Neuro Oncol       Date:  2016-07       Impact factor: 12.300

Review 10.  From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?

Authors:  Norbert Galldiks; Karl-Josef Langen; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-06-30       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.